Leman Biotech is a clinical-stage biotech company redefining next-generation immunotherapy through metabolic reprogramming. Co-founded by EPFL's Professor Li Tang team and XtalPi, we leverage our first-in-class META 10 metabolic reprogramming platform to reverse T cell exhaustion—the key bottleneck in immunotherapy efficacy.

By precisely modulating the IL-10 pathway, META 10 restores proliferation, cytotoxicity, and long-term memory in terminally exhausted T cells, enabling an "ultra-low dose, high efficacy, favorable safety" therapeutic paradigm. Validated in r/r B-ALL, r/r DLBCL, and SLE, our lead candidate META10-19 achieved 100% DORIS remission at 1/1000 dose in SLE—without lymphodepletion or washout—pioneering outpatient-compatible cell therapy.
 

Our proprietary automated, closed, in vivo-like CAR-T production system reduces cost and complexity while improving accessibility. As a modular platform, META 10 empowers CAR-T, TCR-T, TILs, and T-cell engagers across hematological malignancies, autoimmune diseases, and solid tumors.
With programs spanning IIT to IND-enabling stages, Leman Biotech is accelerating global partnerships to deliver ultra-low dose, highly effective, safe, and broadly accessible cell therapies to patients worldwide.